Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 2Advanced Solid Tumor 2Solid Tumor, Adult 1Solid Tumor 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1

Interventions

pembrolizumab 2Bevacizumab 2vanucizumab 1utomilumab 1trifluridine tipiracil drug combination 1selicrelumab 1mogamulizumab 1Trifluridine 1Standard of Care 1N-(6,6-dimethyl-5-((1-methylpiperidin-4-yl)carbonyl)-1,4,5,6-tetrahydropyrrolo(3,4-c)pyrazol-3-yl)-3-methylbutanamide 1Injections 1HMPL-013 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced/Metastatic Solid Tumors × Fulvestrant × Other solid neoplasm × Clear all
NCT07480681 2026-03-18

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

Shanghai Henlius Biotech

Phase 1 Not yet recruiting
138 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡